Associated Papers
Evolutionary history of adenomas to colorectal cancer in FAP families.
Yang C et al.
Frontiers in Genetics, 2024
39021676 (PubMed )
Supplement: DataSheet1.ZIP › Somatic › 18R10487.xls › SNVIndel
Molecular and clinical features of papillary thyroid cancer in adult patients with a non-classical phenotype.
Zhou J et al.
Frontiers in Endocrinology, 2023
37124750 (PubMed )
Supplement: Table_6.xlsx › Sheet1
Multi-omics characterization reveals the pathogenesis of liver focal nodular hyperplasia.
Liu Y et al.
Iscience, 2022
36060063 (PubMed )
Supplement: mmc3.xlsx › Sheet1
Pan-genomic characterization of high-risk pediatric papillary thyroid carcinoma.
Stenman A et al.
Endocrine-related Cancer, 2021
33827048 (PubMed )
Supplement: supplementary_table_1.xlsx › Blad1
Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.
Qi YA et al.
Molecular & Cellular Proteomics : Mcp, 2021
34391887 (PubMed )
Supplement: mmc3.xlsx › RA007.all.somatic
Latency and interval therapy affect the evolution in metastatic colorectal cancer.
Nikbakht H et al.
Scientific Reports, 2020
31953485 (PubMed )
Supplement: 41598_2020_57476_MOESM5_ESM.xlsx › All_non-silent_mutations
Molecular Characterization and Putative Pathogenic Pathways of Tuberous Sclerosis Complex-Associated Renal Cell Carcinoma.
Park JH et al.
Translational Oncology, 2018
29925043 (PubMed )
Supplement: mmc3.xlsx › Table_7
Dissecting the Mutational Landscape of Cutaneous Melanoma: An Omic Analysis Based on Patients from Greece.
Kontogianni G et al.
Cancers, 2018
29596374 (PubMed )
Supplement: cancers-10-00096-s001.zip › Table_S1.xlsx › S1
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.
Schrader A et al.
Nature Communications, 2018
29449575 (PubMed )
Supplement: 41467_2017_2688_MOESM20_ESM.xlsx › e__Freq_TP095
Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma.
Wong SQ et al.
Jco Precision Oncology, 2017
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers MI et al.
Oncotarget, 2016
27791198 (PubMed )
Supplement: oncotarget-07-77163-s002.xlsx › Patient_1_late_met_1
Select a paper to view details